C07C 229/66
The carbon skeleton being further substituted by doubly-bound oxygen atoms
Official title: the carbon skeleton being further substituted by doubly-bound oxygen atoms
C07C229/66 (The carbon skeleton being further substituted by doubly-bound oxygen atoms) appears on 19 US grants and 22 published applications in this corpus.
Search patents in C07C- Granted patents
- 19
- Published applications
- 22
- Assignees
- 17
- Inventors
- 66
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1980 | 1 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 2 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 1 |
| 2009 | 0 | 1 |
| 2010 | 1 | 2 |
| 2011 | 1 | 1 |
| 2012 | 1 | 2 |
| 2013 | 2 | 2 |
| 2014 | 2 | 5 |
| 2015 | 2 | 2 |
| 2016 | 1 | 0 |
| 2017 | 1 | 3 |
| 2018 | 1 | 0 |
| 2019 | 0 | 0 |
| 2020 | 0 | 0 |
| 2021 | 0 | 0 |
| 2022 | 0 | 0 |
| 2023 | 0 | 0 |
| 2024 | 1 | 1 |
| 2025 | 0 | 1 |
| 2026 | 1 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Solid forms, salts and polymorphs of anti-fibrotic compounds6 Oct 2026US 12,753,148 B2Certa Therapeutics Pty Ltd
- Solid forms, salts and polymorphs of anti-fibrotic compounds20 Feb 2024US 11,905,231 B1Certa Therapeutics Pty Ltd
- LED photoinitiators10 Apr 2018US 9,938,232 B2Sun Chemical Corporation
- Process for making modulators of cystic fibrosis transmembrane conductance regulator5 Sep 2017US 9,751,839 B2Vertex Pharmaceuticals Incorporated
- Process for making modulators of cystic fibrosis transmembrane conductance regulator21 Jun 2016US 9,371,287 B2Vertex Pharmaceuticals Incorporated
- New process for the manufacture of mdm2-p53 antagonists23 Jul 2026US 2026/0209169 A1Boehringer Ingelheim International GmbH
- Metabotropic glutamate receptor positive allosteric modulators (pams) and uses thereof5 Jun 2025US 2025/0179000 A1Sanford Burnham Prebys Medical Discovery Institute
- Solid Forms, Salts and Polymorphs of Anti-fibrotic Compounds8 Aug 2024US 2024/0262785 A1Certa Therapeutics Pty Ltd
- Process for making modulators of cystic fibrosis transmembrane conductance regulator16 Nov 2017US 2017/0327456 A1Vertex Pharmaceuticals Incorporated
- Process for making modulators of cystic fibrosis transmembrane conductance regulator6 Apr 2017US 2017/0096396 A1Vertex Pharmaceuticals Incorporated
Most cited
By later US patents
- Process for making modulators of cystic fibrosis transmembrane conductance regulator83US 8,476,442 B2Vertex Pharmaceutical Incorporated · 2013
- Process for making modulators of cystic fibrosis transmembrane conductance regulator71US 8,765,957 B2Vertex Pharmaceuticals Incorporated · 2014
- Process for making modulators of cystic fibrosis transmembrane conductance regulator70US 8,835,639 B2Vertex Pharmaceuticals Incorporated · 2014
- Process for making modulators of cystic fibrosis transmembrane conductance regulator55US 9,371,287 B2Vertex Pharmaceuticals Incorporated · 2016
- Process for making modulators of cystic fibrosis transmembrane conductance regulator41US 9,751,839 B2Vertex Pharmaceuticals Incorporated · 2017